Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Regeneron Pharmaceuticals, Inc. (REGN) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron Pharmaceuticals, Inc. (REGN) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for January 3rd
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 3rd:
Sarepta Therapeutics, Inc. (SRPT - Free Report) : This clinical-stage biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.6% over the last 60 days.
Sarepta Therapeutics, Inc. Price and Consensus
Sarepta Therapeutics, Inc. price-consensus-chart | Sarepta Therapeutics, Inc. Quote
Sarepta’s shares gained 11.7% over the last month compared with the S&P 500’s advance of 4.3%. The company possesses a Momentum Score of A.
Sarepta Therapeutics, Inc. Price
Sarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote
Wingstop Inc. (WING - Free Report) : This restaurant franchise has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.1% over the last 60 days.
Wingstop Inc. Price and Consensus
Wingstop Inc. price-consensus-chart | Wingstop Inc. Quote
Wingstop’s shares gained 36.7% over the last three months compared with the S&P 500’s advance of 11.2%. The company possesses a Momentum Score of A.
Wingstop Inc. Price
Wingstop Inc. price | Wingstop Inc. Quote
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) : This biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.3% over the last 60 days.
Regeneron Pharmaceuticals, Inc. Price and Consensus
Regeneron Pharmaceuticals, Inc. price-consensus-chart | Regeneron Pharmaceuticals, Inc. Quote
Regeneron’s shares gained 26.1% over the last six months compared with the S&P 500’s advance of 7%. The company possesses a Momentum Score of A.
Regeneron Pharmaceuticals, Inc. Price
Regeneron Pharmaceuticals, Inc. price | Regeneron Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.